LaNova Medicines’ Next-Generation Nectin-4 ADC LM-364 Wins China IND Clearance for Advanced Solid Tumors
LaNova Medicines has received clearance from China’s National Medical Products Administration (NMPA) to advance LM-364, its next-generation tumor microenvironment-responsive Nectin-4 antibody-drug conjugate (ADC), into clinical development for patients…